SDHB and metastatic neoplasm: Even paragangliomas and pheochromocytomas associated with succinate dehydrogenase subunit B (SDHB) variants, which may result in aggressive metastatic disease and fatal outcomes, show an overall 5-year survival of 76%-85% [12, 14].